BIO002 Evaluation of osteogenic effect by different phyestrogens in osteoblasts culture derived from mesenchymal stem cells
Resumo
Menopause is caused by the failure of ovarian hormones production and can produce unfavorable changes in lipid, glucose and insulin metabolism, in the coagulation/fibrinolysis system, as well as bone loss are some of its consequences. One of the current concerns is the relationship between the decrease in estrogen production and bone mass loss, which is considered a major risk factor for the development of osteoporosis in women. Osteoporosis is currently considered a worldwide public health problem and it is estimated that by 2030, more than one billion and 200 million women will be menopausal. One of the ways to treat menopause symptoms and decrease the chance of someone to develop osteoporosis is the use of the Hormone Replacement Therapy (HRT). However, this therapy has brought some risks to the health of some groups of women, especially those with a history of thromboembolic diseases and breast cancer in their families, and the use of phytoestrogens such as isoflavones is an alternative to the traditional treatment. Isoflavones are found mainly in soybeans (Glycine max), red clover (Trifolium pratense), Cimicifuga racemosa (of American origin) and rye.Downloads
Não há dados estatísticos.
Downloads
Publicado
2012-12-27
Como Citar
DE FARIA, A. N.; CIANCAGLINI, P.; SIMÃO, A. M. S.; ZANCANELA, D. C.; FONSECA, M. J. V.; TORQUETI, M. R. BIO002 Evaluation of osteogenic effect by different phyestrogens in osteoblasts culture derived from mesenchymal stem cells. Revista Eletrônica de Farmácia, Goiânia, v. 9, n. 1, p. 1, 2012. Disponível em: https://revistas.ufg.br/REF/article/view/21896. Acesso em: 22 dez. 2024.
Edição
Seção
Artigos Originais
Licença
Copyright (c) 2021 Revista Eletrônica de Farmácia
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Termo de responsabilidade de autoria e acordo de transferência do copyright, indicando a categoria do artigo, segundo as definições explicitadas nestas normas, responsabilizando os autores quanto a existência de plágio e autorizando a Revista Eletrônica de Farmácia sua publicação, devem estar assinados por todos os autores e anexado ao sistema como documento suplementar no momento de submissão do manuscrito.
Os direitos autorais da versão final do artigo são de propriedade da REF. O conteúdo da Revista ficará disponível para toda a comunidade científica.